Communiqués Lonza Group AG

Actions

LONN

CH0013841017

Marché Fermé - Swiss Exchange Autres places de cotation 17:30:19 12/06/2024			Varia. 5j.	Varia. 1 janv.
485,1 ^CHF	-2,02 %		-2,79 %	+37,15 %

31/05	Derniers écueils avant les baisses de taux ?
31/05	AVIS D'ANALYSTES DU JOUR : Capgemini, Saint-Gobain, Neoen, Derichebourg, Lonza, Ahold, Richemont...

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lonza : Q1 2024 Qualitative Update	14/05	PU
Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024	14/05	EQ
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved	08/05	EQ
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon	17/04	EQ
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports	03/04	EQ
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer	02/04	EQ
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche	20/03	EQ
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza	26/01	EQ
Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin	26/01	EQ
Lonza : Launches GS Effex® Cell Line for the Development of Therapeutic Antibodies with Increased Potency	14/11	PU
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds	06/11	EQ
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects	17/10/23	EQ
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer	13/10/23	EQ
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023	21/09/23	EQ
Board Announcement	18/09/23	EQ
Lonza : Half-Year 2023 Results Report	21/07/23	PU
Lonza Delivers 5.6% CER Sales Growth, With Underlying Growth at Around 10% CER and 30% CORE EBITDA Margin	21/07/23	EQ
Lonza : Launches TheraPRO® CHO Media System to Improve Productivity and Quality in Therapeutic Protein Manufacture	17/07/23	PU
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes Cell Therapies	27/06/23	AQ
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering	01/06/23	EQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

GROUPE LONZA : Des effets réels mitigés

Le 06 février 2024 à 16:44

Lonza, le couteau suisse de l'industrie pharmaceutique

Le 11 octobre 2022 à 11:32